Arvinas, Inc. (ARVN): Price and Financial Metrics

Arvinas, Inc. (ARVN)

Today's Latest Price: $27.01 USD

1.84 (7.31%)

Updated Dec 4 4:00pm

Add ARVN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ARVN Stock Summary

  • ARVN's went public 2.19 years ago, making it older than just 5.21% of listed US stocks we're tracking.
  • For ARVN, its debt to operating expenses ratio is greater than that reported by just 6.98% of US equities we're observing.
  • ARVN's price/sales ratio is 41.83; that's higher than the P/S ratio of 94.81% of US stocks.
  • Stocks that are quantitatively similar to ARVN, based on their financial statements, market capitalization, and price volatility, are CUE, ASMB, NKTR, ZYME, and BLUE.
  • ARVN's SEC filings can be seen here. And to visit Arvinas Inc's official web site, go to

ARVN Stock Price Chart Interactive Chart >

Price chart for ARVN

ARVN Price/Volume Stats

Current price $27.01 52-week high $61.57
Prev. close $25.17 52-week low $19.68
Day low $25.00 Volume 476,000
Day high $27.09 Avg. volume 461,377
50-day MA $23.53 Dividend yield N/A
200-day MA $33.92 Market Cap 1.10B

Arvinas, Inc. (ARVN) Company Bio

Arvinas Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.

ARVN Latest News Stream

Event/Time News Detail
Loading, please wait...

ARVN Latest Social Stream

Loading social stream, please wait...

View Full ARVN Social Stream

Latest ARVN News From Around the Web

Below are the latest news stories about Arvinas Inc that investors may wish to consider to help them evaluate ARVN as an investment opportunity.

ESSA's Novel Prostate Cancer Treatment In Clinical Trial: Pfizer Is New Lead Investor

ESSA Pharma Inc. (NASDAQ:EPIX) [TSX-V: EPI] is a Canadian/U.S. clinical-stage pharmaceutical company which recently began Phase 1 clinical trials for its lead drug EPI-7386, a novel treatment for men with castration-resistant prostate cancer ("CRPC") where the cancer is progressing despite the men having been treated with current standard of care...

Steven Goldman on Seeking Alpha | August 19, 2020

IPO Update: Kymera Therapeutics Readies $125 Million IPO

Quick Take Kymera Therapeutics (KYMR) intends to raise $125 million from the sale of its common stock in an IPO, according to an amended registration statement. The company is advancing treatment candidates for skin and immune system conditions. KYMR is still some time away from beginning Phase 1 safety trials...

Donovan Jones on Seeking Alpha | August 17, 2020

The Arvinas (NASDAQ:ARVN) Share Price Has Gained 30% And Shareholders Are Hoping For More

The last three months have been tough on Arvinas, Inc. (NASDAQ:ARVN) shareholders, who have seen the share price...

Yahoo | July 30, 2020

Did Hedge Funds Make The Right Call On Arvinas, Inc. (ARVN) ?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

Yahoo | July 20, 2020

Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors

NEW HAVEN, Conn., June 29, 2020 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,.

Yahoo | June 29, 2020

Read More 'ARVN' Stories Here

ARVN Price Returns

1-mo 21.39%
3-mo 9.75%
6-mo -24.04%
1-year -29.70%
3-year N/A
5-year N/A
YTD -34.27%
2019 219.77%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching ARVN

Here are a few links from around the web to help you further your research on Arvinas Inc's stock as an investment opportunity:

Arvinas Inc (ARVN) Stock Price | Nasdaq
Arvinas Inc (ARVN) Stock Quote, History and News - Yahoo Finance
Arvinas Inc (ARVN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8278 seconds.